Company research
Barinthus Biotherapeutics plc.
CIK 1828185Updated Oct 6, 2026
Historical securities (1)
BRNS · NASDAQ · adr · closed Sep 8, 2026BRNS price & chart
This listing closed Sep 8, 2026. Live provider charts are shown only for current listings.
About the company
Barinthus Biotherapeutics (NASDAQ: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people and their families living with serious diseases is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity including: VTP-1000, which utilizes the Company's SNAP-Tolerance Immunotherapy (SNAP-TI) platform and is designed to treat people with celiac disease. Barinthus Bio’s differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, positions the Company to navigate towards delivering treatments that improve the lives of people with autoimmunity. For more information, visit www.barinthusbio.com.
In the news
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders? ↗
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights News provided by Halper Sadeh LLP Nov 19, 2025, 18:18 ET Share this article Share to X Share this article Share to X Shareholders should contact the firm immediately as there may be limited ti ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 109,201,000Source | 188,689,000Source | 81,893,000Source | 129,561,000Source | 186,749,000Source | 92,143,000Source | 141,996,000Source | 199,482,000Source | 98,169,000Source | 160,327,000Source | 214,506,000Source | 270,205,000Source |
| Property, Plant and Equipment, NetUSD | 4,519,000Source | 10,719,000Source | 3,038,000Source | 4,514,000Source | 10,962,000Source | 3,270,000Source | 6,201,000Source | 11,532,000Source | 3,523,000Source | 7,373,000Source | 11,821,000Source | 7,957,000Source |
| GoodwillUSD | — | 12,209,000Source | — | — | 12,209,000Source | — | — | 12,209,000Source | — | 0Source | 12,209,000Source | 12,209,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 14,909,000Source | 22,737,000Source | 13,045,000Source | 20,366,000Source | 23,527,000Source | 13,666,000Source | 21,156,000Source | 24,317,000Source | 14,288,000Source | 21,947,000Source | 25,108,000Source | 28,269,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 74,272,000Source | — | 59,295,000Source | 86,259,000Source | — | 65,858,000Source | 99,118,000Source | — | 70,456,000Source | 110,662,000Source | 142,090,000Source | 194,385,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 323,000Source |
| Assets, CurrentUSD | 86,781,000Source | 134,654,000Source | 63,273,000Source | 100,414,000Source | 131,879,000Source | 72,664,000Source | 109,882,000Source | 143,131,000Source | 77,790,000Source | 125,742,000Source | 156,905,000Source | 213,041,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,336,000Source | 8,180,000Source | 2,362,000Source | 7,681,000Source | 9,582,000Source | 4,243,000Source | 6,306,000Source | 7,964,000Source | 4,830,000Source | 6,203,000Source | 9,907,000Source | 8,268,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,063,000Source | 7,444,000Source | 1,618,000Source | 3,323,000Source | 7,286,000Source | 1,629,000Source | 3,855,000Source | 7,408,000Source | 1,638,000Source | 4,384,000Source | 7,581,000Source | 7,753,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 24,640,000Source | 29,228,000Source | 24,759,000Source | 27,080,000Source | 29,959,000Source | 25,665,000Source | 26,403,000Source | 27,466,000Source | 23,877,000Source | 30,192,000Source | 27,511,000Source | 27,004,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 393,248,000Source | 391,882,000Source | 394,932,000Source | 393,663,000Source | 390,273,000Source | 394,499,000Source | 393,944,000Source | 388,720,000Source | 393,944,000Source | 393,474,000Source | 386,602,000Source | 379,504,000Source |
| Retained Earnings (Accumulated Deficit)USD | -293,002,000Source | -217,124,000Source | -320,208,000Source | -278,436,000Source | -209,010,000Source | -309,628,000Source | -257,312,000Source | -192,079,000Source | -304,092,000Source | -237,664,000Source | -176,590,000Source | -103,243,000Source |
| Stockholders' Equity Attributable to ParentUSD | 84,465,000Source | 159,294,000Source | 57,073,000Source | 102,377,000Source | 156,618,000Source | 66,399,000Source | 115,494,000Source | 171,833,000Source | 74,208,000Source | 130,029,000Source | 186,784,000Source | 242,896,000Source |
| Liabilities and EquityUSD | 109,201,000Source | 188,689,000Source | 81,893,000Source | 129,561,000Source | 186,749,000Source | 92,143,000Source | 141,996,000Source | 199,482,000Source | 98,169,000Source | 160,327,000Source | 214,506,000Source | 270,205,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,798,000Source | 15,072,000Source | 11,423,000Source | 12,725,000Source | 15,589,000Source | 12,001,000Source | 11,976,000Source | 12,835,000Source | 10,018,000Source | 15,657,000Source | 12,598,000Source | 12,242,000Source |
| Operating Lease, Liability, CurrentUSD | 2,017,000Source | 1,986,000Source | 1,724,000Source | 2,036,000Source | 1,916,000Source | 2,005,000Source | 1,960,000Source | 1,909,000Source | 2,023,000Source | 1,920,000Source | 1,785,000Source | 433,000Source |
| Accounts Payable, CurrentUSD | 698,000Source | 3,076,000Source | 535,000Source | 1,800,000Source | 2,556,000Source | 993,000Source | 1,357,000Source | 1,162,000Source | 350,000Source | 2,474,000Source | 1,601,000Source | 3,748,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,553,000Source | 10,683,000Source | 8,571,000Source | 9,952,000Source | 10,654,000Source | 9,003,000Source | 9,959,000Source | 10,897,000Source | 9,258,000Source | 10,087,000Source | 11,191,000Source | 8,340,000Source |
| Deferred Income Tax Liabilities, NetUSD | 320,000Source | 457,000Source | 215,000Source | 391,000Source | — | 237,000Source | 416,000Source | — | 254,000Source | 438,000Source | 11,750,000Source | 12,680,000Source |
| Other Liabilities, NoncurrentUSD | 1,461,000Source | 1,406,000Source | 1,487,000Source | 1,468,000Source | 1,338,000Source | 1,468,000Source | 1,400,000Source | 1,330,000Source | 1,476,000Source | 1,360,000Source | 1,325,000Source | 965,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 96,000Source | 167,000Source | 61,000Source | 104,000Source | 172,000Source | 79,000Source | 99,000Source | 183,000Source | 84,000Source | 106,000Source | 211,000Source | 305,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 574,000Source | 3,746,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -14,571,000Source | -8,129,000Source | -10,599,000Source | -21,126,000Source | -5,534,000Source | -19,658,000Source | -66,458,000Source | -61,183,000Source | -73,447,000Source | 5,321,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 856,000Source | 2,034,000Source | 5,845,000Source | 5,800,000Source | 5,429,000Source | 4,323,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 556,000Source | 468,000Source | 468,000Source | 4,709,000Source | 5,055,000Source | 9,877,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | 0Source | -5,800,000Source | 5,833,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 644,000Source | -1,155,000Source | -2,202,000Source | 898,000Source | -3,378,000Source | 1,140,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -16,000Source | -22,000Source | -175,000Source | -44,000Source | -3,075,000Source | -4,337,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,366,000Source | -14,902,000Source | -47,979,000Source | -28,940,000Source | -50,925,000Source | -14,431,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 55,000Source | -5,000Source | 416,000Source | -892,000Source | -5,413,000Source | -5,750,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 5,000Source | 37,000Source | 892,000Source | 5,413,000Source | 6,138,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 2,000Source | 2,000Source | 2,163,000Source | 1,872,000Source | 325,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -4,663,000Source | -11,821,000Source | -40,548,000Source | -29,690,000Source | -52,295,000Source | -19,669,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 75,674,000Source | 106,102,000Source | 59,630,000Source | 87,784,000Source | 67,189,000Source | 100,579,000Source | 71,852,000Source | 112,400,000Source | 142,090,000Source | 194,385,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | -415,000Source | 1,144,000Source | 433,000Source | -281,000Source | 556,000Source | 468,000Source | 468,000Source | 4,709,000Source | 5,055,000Source | 9,877,000Source |
| Amortization of Intangible AssetsUSD | — | — | 800,000Source | 800,000Source | 600,000Source | 800,000Source | 600,000Source | 800,000Source | 3,000,000Source | 3,200,000Source | 3,200,000Source | 3,200,000Source |
| DepreciationUSD | — | — | 100,000Source | 700,000Source | 200,000Source | 1,200,000Source | 200,000Source | 1,200,000Source | 2,900,000Source | 2,600,000Source | 2,300,000Source | 1,100,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 3,000,000Source | -7,700,000Source | -900,000Source | -8,000,000Source | 3,000,000Source | -4,400,000Source | -9,600,000Source | 2,400,000Source | -7,600,000Source | 26,400,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | 1,714,000Source | -1,587,000Source | -3,742,000Source | 649,000Source | -7,531,000Source | 24,905,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | 100,000Source | 300,000Source | 38,000Source | 0Source | 245,000Source | — | 0Source | 348,000Source |
| General and Administrative ExpenseUSD | — | — | 5,165,000Source | 13,420,000Source | 7,101,000Source | 15,384,000Source | 2,528,000Source | 12,639,000Source | 40,830,000Source | 29,670,000Source | 39,842,000Source | 6,394,000Source |
| GoodwillUSD | — | — | — | 12,209,000Source | — | — | — | — | — | 0Source | 12,209,000Source | 12,209,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 12,209,000Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 4,667,000Source | 0Source | — | — | — | — | 4,667,000Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | -71,000Source | -3,000Source | -23,000Source | -25,000Source | -16,000Source | -22,000Source | -175,000Source | -44,000Source | -3,075,000Source | -4,471,000Source |
| InterestExpenseNonoperatingUSD | — | — | 13,000Source | 17,000Source | 14,000Source | 12,000Source | 13,000Source | 13,000Source | 51,000Source | 53,000Source | — | — |
| Investment Income, InterestUSD | — | — | 472,000Source | 631,000Source | 343,000Source | 523,000Source | 350,000Source | 556,000Source | 1,957,000Source | 2,678,000Source | 2,877,000Source | 3,103,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,566,000Source | -8,114,000Source | -10,580,000Source | -21,124,000Source | -5,531,000Source | -19,648,000Source | -66,428,000Source | -61,074,000Source | -73,347,000Source | 5,342,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -5,000Source | -15,000Source | -19,000Source | -2,000Source | -3,000Source | -10,000Source | -30,000Source | -109,000Source | -100,000Source | -21,000Source |
| Nonoperating Income (Expense)USD | — | — | 424,000Source | 1,248,000Source | 397,000Source | 2,173,000Source | 525,000Source | 920,000Source | 3,922,000Source | 6,743,000Source | 7,392,000Source | 4,891,000Source |
| Operating ExpensesUSD | — | — | 15,222,000Source | 24,559,000Source | 11,024,000Source | 23,337,000Source | 6,121,000Source | 20,929,000Source | 71,061,000Source | 84,115,000Source | 84,716,000Source | 48,744,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 400,000Source | 2,600,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -275,000Source | 26,000Source | 26,000Source | 320,000Source | 39,000Source | 75,000Source | 16,000Source | 135,000Source | 1,082,000Source | 567,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 2,163,000Source | 2,035,000Source | 484,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 14,969,000Source | — | — | — | — | 0Source | 14,969,000Source | 802,000Source | 44,703,000Source |
| Operating Income (Loss)USD | — | — | -15,066,000Source | -9,380,000Source | -11,019,000Source | -23,324,000Source | -6,075,000Source | -20,600,000Source | -70,555,000Source | -67,970,000Source | -83,914,000Source | -4,041,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -275,000Source | 26,000Source | 26,000Source | 320,000Source | 39,000Source | 75,000Source | 16,000Source | 135,000Source | 1,082,000Source | 567,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -14,642,000Source | -8,132,000Source | -10,622,000Source | -21,151,000Source | -5,550,000Source | -19,680,000Source | -66,633,000Source | -61,227,000Source | -76,522,000Source | 850,000Source |
| Income Tax Expense (Benefit)USD | — | — | -71,000Source | -3,000Source | -23,000Source | -25,000Source | -16,000Source | -22,000Source | -175,000Source | -44,000Source | -3,075,000Source | -4,471,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -5,000Source | -15,000Source | -19,000Source | -2,000Source | -3,000Source | -10,000Source | -30,000Source | -109,000Source | -100,000Source | -21,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,566,000Source | -8,114,000Source | -10,580,000Source | -21,124,000Source | -5,531,000Source | -19,648,000Source | -66,428,000Source | -61,074,000Source | -73,347,000Source | 5,342,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.36Source | -0.21Source | -0.26Source | -0.52Source | -0.14Source | -0.49Source | -1.64Source | -1.55Source | -1.91Source | 0.14Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.36Source | -0.21Source | -0.26Source | -0.52Source | -0.14Source | -0.49Source | -1.64Source | -1.55Source | -1.91Source | 0.14Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 40,661,118Source | 39,419,447Source | 40,848,893Source | 40,343,521Source | 40,848,893Source | 40,265,216Source | 40,527,218Source | 39,348,240Source | 38,386,491Source | 37,248,126Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 40,661,118Source | 39,419,447Source | 40,848,893Source | 40,343,521Source | 40,848,893Source | 40,265,216Source | 40,527,218Source | 39,348,240Source | 38,386,491Source | 38,169,307Source |
| Interest Expense (non-operating)USD | — | — | 13,000Source | 17,000Source | 14,000Source | 12,000Source | 13,000Source | 13,000Source | 51,000Source | 53,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 800,000Source | 800,000Source | 600,000Source | 800,000Source | 600,000Source | 800,000Source | 3,000,000Source | 3,200,000Source | 3,200,000Source | 3,200,000Source |
| Business Combination, Acquisition Related CostsUSD | — | — | — | — | 1,500,000Source | 0Source | 3,700,000Source | 0Source | 2,800,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 3,000,000Source | -7,700,000Source | -900,000Source | -8,000,000Source | 3,000,000Source | -4,400,000Source | -9,600,000Source | 2,400,000Source | -7,600,000Source | 26,400,000Source |
| General and Administrative ExpenseUSD | — | — | 5,165,000Source | 13,420,000Source | 7,101,000Source | 15,384,000Source | 2,528,000Source | 12,639,000Source | 40,830,000Source | 29,670,000Source | 39,842,000Source | 6,394,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 12,209,000Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -42,544,000Source | -27,510,000Source | -50,534,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 28,000Source | 19,000Source |
| Investment Income, InterestUSD | — | — | 472,000Source | 631,000Source | 343,000Source | 523,000Source | 350,000Source | 556,000Source | 1,957,000Source | 2,678,000Source | 2,877,000Source | 3,103,000Source |
| Nonoperating Income (Expense)USD | — | — | 424,000Source | 1,248,000Source | 397,000Source | 2,173,000Source | 525,000Source | 920,000Source | 3,922,000Source | 6,743,000Source | 7,392,000Source | 4,891,000Source |
| Operating ExpensesUSD | — | — | 15,222,000Source | 24,559,000Source | 11,024,000Source | 23,337,000Source | 6,121,000Source | 20,929,000Source | 71,061,000Source | 84,115,000Source | 84,716,000Source | 48,744,000Source |
| Other Operating IncomeUSD | — | — | 156,000Source | 210,000Source | 5,000Source | 13,000Source | 46,000Source | 329,000Source | 506,000Source | 1,176,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 5,390,000Source | 11,139,000Source | 3,923,000Source | 7,953,000Source | 3,593,000Source | 8,290,000Source | 25,564,000Source | 42,236,000Source | 44,874,000Source | 42,350,000Source |
Offerings
Registration 333-265763
Filing attachments
tm2623930d1_ex99-1.htm · 8-K · 2026-08-25
EX-99.1 2 tm2623930d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open ───────────────────────────────────────────────────────────────────────────────────────────── Top…
Read attachment ↗